These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 9370080)

  • 1. Adoptive immunotherapy.
    Ballen K; Stewart FM
    Curr Opin Oncol; 1997 Nov; 9(6):579-83. PubMed ID: 9370080
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Allogeneic hematopoietic stem cell transplantation for solid tumors in the United States: a review].
    Cheng YC; Ueno NT
    Nihon Rinsho; 2003 Sep; 61(9):1619-34. PubMed ID: 14515734
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adoptive cellular therapy of malignancy.
    Chang AE; Geiger JD; Sondak VK; Shu S
    Arch Surg; 1993 Nov; 128(11):1281-90. PubMed ID: 8239992
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Active vaccination after allogeneic bone marrow cell transplantation: a new option in the immunotherapy of cancer?
    Zöller M; Matzku S
    Arch Immunol Ther Exp (Warsz); 2002; 50(3):197-224. PubMed ID: 12098935
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cellular therapy.
    Hersey P
    Curr Opin Oncol; 1993 Nov; 5(6):1049-54. PubMed ID: 8305538
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activation of T lymphocytes for the adoptive immunotherapy of cancer.
    Sussman JJ; Shu S; Sondak VK; Chang AE
    Ann Surg Oncol; 1994 Jul; 1(4):296-306. PubMed ID: 7850528
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cellular therapy to control tumor progression.
    Kapp M; Rasche L; Einsele H; Grigoleit GU
    Curr Opin Hematol; 2009 Nov; 16(6):437-43. PubMed ID: 19587587
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nonmyeloablative stem cell transplantation for the treatment of cancer and life-threatening nonmalignant disorders: past accomplishments and future goals.
    Slavin S; Or R; Aker M; Shapira MY; Panigrahi S; Symeonidis A; Cividalli G; Nagler A
    Cancer Chemother Pharmacol; 2001 Aug; 48 Suppl 1():S79-84. PubMed ID: 11587373
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Importance of cyclophosphamide-induced bystander effect on T cells for a successful tumor eradication in response to adoptive immunotherapy in mice.
    Proietti E; Greco G; Garrone B; Baccarini S; Mauri C; Venditti M; Carlei D; Belardelli F
    J Clin Invest; 1998 Jan; 101(2):429-41. PubMed ID: 9435316
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adoptive immunotherapy of cancer: accomplishments and prospects.
    Rosenberg SA
    Cancer Treat Rep; 1984 Jan; 68(1):233-55. PubMed ID: 6362866
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adoptive immunotherapy with virus-specific T cells.
    Fuji S; Kapp M; Grigoleit GU; Einsele H
    Best Pract Res Clin Haematol; 2011 Sep; 24(3):413-9. PubMed ID: 21925094
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Donor lymphocyte infusion: the use of alloreactive and tumor-reactive lymphocytes for immunotherapy of malignant and nonmalignant diseases in conjunction with allogeneic stem cell transplantation.
    Slavin S; Morecki S; Weiss L; Or R
    J Hematother Stem Cell Res; 2002 Apr; 11(2):265-76. PubMed ID: 11983098
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunotherapy for Epstein-Barr virus-associated tumors.
    Comito MA; Sun Q; Lucas KG
    Leuk Lymphoma; 2004 Oct; 45(10):1981-7. PubMed ID: 15370241
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epstein-Barr virus-specific adoptive immunotherapy for recurrent, metastatic nasopharyngeal carcinoma.
    Huang J; Fogg M; Wirth LJ; Daley H; Ritz J; Posner MR; Wang FC; Lorch JH
    Cancer; 2017 Jul; 123(14):2642-2650. PubMed ID: 28222215
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adoptive immunotherapy with allogeneic Epstein-Barr virus (EBV)-specific cytotoxic T-lymphocytes for recurrent, EBV-positive Hodgkin disease.
    Lucas KG; Salzman D; Garcia A; Sun Q
    Cancer; 2004 May; 100(9):1892-901. PubMed ID: 15112270
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical applications of adoptive natural killer cell immunotherapy for cancer: current status and future prospects.
    Guo H; Qian X
    Onkologie; 2010; 33(7):389-95. PubMed ID: 20631487
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chimeric antigen receptor engineering: a right step in the evolution of adoptive cellular immunotherapy.
    Figueroa JA; Reidy A; Mirandola L; Trotter K; Suvorava N; Figueroa A; Konala V; Aulakh A; Littlefield L; Grizzi F; Rahman RL; Jenkins MR; Musgrove B; Radhi S; D'Cunha N; D'Cunha LN; Hermonat PL; Cobos E; Chiriva-Internati M
    Int Rev Immunol; 2015 Mar; 34(2):154-87. PubMed ID: 25901860
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cell therapy: achievements and perspectives.
    Bordignon C; Carlo-Stella C; Colombo MP; De Vincentiis A; Lanata L; Lemoli RM; Locatelli F; Olivieri A; Rondelli D; Zanon P; Tura S
    Haematologica; 1999 Dec; 84(12):1110-49. PubMed ID: 10586214
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adoptive cellular immunotherapy for childhood malignancies.
    Cooper LJ
    Bone Marrow Transplant; 2008 Jan; 41(2):183-92. PubMed ID: 18026145
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunotherapy and gene therapy.
    Simpson E
    IDrugs; 2004 Feb; 7(2):105-8. PubMed ID: 15057648
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.